Literature DB >> 17083991

A bidirectional Tet-dependent promotor construct regulating the expression of E1A for tight control of oncolytic adenovirus replication.

Henry Fechner1, Xiaomin Wang, Almudena Hurtado Picó, Judith Wildner, Lennart Suckau, Sandra Pinkert, Isaac Sipo, Stefan Weger, Wolfgang Poller.   

Abstract

Tight regulation of oncolytic adenoviruses (oAdV) represents an important requirement for their safe application. Here we describe a new doxycycline (Dox)-dependent oAdV with a bidirectional expression cassette, which drives the expression of the reverse tetracycline-controlled transactivator (rtTA(s)-M2) from a lung tumor-specific promoter and, in the opposite direction, the expression of the adenoviral E1A gene from a second generation TetO(7) sequence linked to an isolated TATA box. In H441 lung cancer cells, this oAdV showed a strictly Dox-dependent E1A expression, adenoviral replication, cell killing activity and a 450-fold induction of progeny virus production. The virus could be shut off again by withdrawal of Dox and, in contrast to a control oAdV expressing E1A directly from the SP-B promoter, did not replicate in non-target cells. However, the absolute values of virus production and the cell killing activity in the presence of the inducer were still reduced as compared to the control oAdV. The results demonstrate, for the first time, Dox-dependent oAdV replication from a single adenoviral vector genome. Future improvement of the Dox-dependent E1A regulation cassette should lead to the generation of an oAdV well suited to meet the demands for a highly regulated and efficient oncolytic virus for in vivo applications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17083991     DOI: 10.1016/j.jbiotec.2006.09.011

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  7 in total

1.  A Hoxb13-driven reverse tetracycline transactivator system for conditional gene expression in the prostate.

Authors:  Varsha Rao; Jamie C Heard; Helya Ghaffari; Aminah Wali; Laura N Mutton; Charles J Bieberich
Journal:  Prostate       Date:  2012-02-01       Impact factor: 4.104

2.  Switching a replication-defective adenoviral vector into a replication-competent, oncolytic adenovirus.

Authors:  Hiroshi Nakashima; E Antonio Chiocca
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

Review 3.  Turning the gene tap off; implications of regulating gene expression for cancer therapeutics.

Authors:  James F Curtin; Marianela Candolfi; Weidong Xiong; Pedro R Lowenstein; Maria G Castro
Journal:  Mol Cancer Ther       Date:  2008-03       Impact factor: 6.261

Review 4.  Cellular targeting for cochlear gene therapy.

Authors:  Allen F Ryan; Lina M Mullen; Joni K Doherty
Journal:  Adv Otorhinolaryngol       Date:  2009-06-02

5.  Mutant sodium channel for tumor therapy.

Authors:  Bakhos A Tannous; Adam P Christensen; Lisa Pike; Thomas Wurdinger; Katherine F Perry; Okay Saydam; Andreas H Jacobs; Jaime García-Añoveros; Ralph Weissleder; Miguel Sena-Esteves; David P Corey; Xandra O Breakefield
Journal:  Mol Ther       Date:  2009-03-03       Impact factor: 11.454

6.  Development of chimeric gene regulators for cancer-specific gene therapy with both transcriptional and translational targeting.

Authors:  Yu Xiang Fang; Xiao Bo Zhang; Wei Wei; Yi Wen Liu; Jin Zhong Chen; Jing Lun Xue; Ling Tian
Journal:  Mol Biotechnol       Date:  2010-05       Impact factor: 2.695

7.  Chemogenetic ON and OFF switches for RNA virus replication.

Authors:  E Heilmann; J Kimpel; B Hofer; A Rössler; I Blaas; L Egerer; T Nolden; C Urbiola; H G Kräusslich; G Wollmann; D von Laer
Journal:  Nat Commun       Date:  2021-03-01       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.